|
(Health-NewsWire.Net, July 31, 2015 ) This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects.
Inquire more about this Report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=397261 . (This is a premium report price at US$2000 for a single user PDF license)
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Scope:
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=397261 . (This is a premium report price at US$2000 for a single user PDF license)
Reasons to Buy:
• Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza)
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
More reports on infectious diseases therapeutics are available at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .
Some of the reports are:
• Investigation Report on China Tobramycin Market, 2010-2019
• Global Clotrimazole Industry Report 2015
• Anti-infectious Disease Drugs Markets in China
• 2015 Toltrazuril (CAS 69004-03-1) Industry Report - Global and Chinese Market Scenario
RnR Market Research
Ritesh Tiwari
+ 1 888 391 5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
